The alliances have evolved and faced the challenges together to build a healthy tomorrow. The latest partnership has been introduced in the vast healthcare market. The PolyActiva, a clinical-level biopharmaceutical company standing in a well-defined position with the novel drug delivery technology to enhance the outcome of ocular patients, have entered a mission-oriented partnership with RareSight Inc. RareSight, Inc. is an ophthalmology-centric life sciences company dedicated to improving therapies for inherited retinal diseases (IRDs).
The strategic partnership came into force to establish the first-ever therapies for rare pediatric retinal diseases that have no such approval for drug treatments. The Research Collaboration Agreement (RCA) is accelerating PolyActiva’s exclusive PREZIA™ platform that provides new chemical entity (NCE)-qualified pro-drug candidates to the group impacted by the blinding eye conditions. The approach of administering intravitreally will serve zero-order, sustained-release treatment straight to the retina with no need for patient administration. This is a major advantage for kids and their caregivers.
The partnership with RareSight extends PolyActiva’s clinical-level ophthalmic portfolio. The portfolio involves PA5108, a biodegradable ocular micro-implant and new chemical alliance engineered for well-sustained intraocular pressure control covering six months with regular dosing with the help of the PREZIA platform. The PolyActiva’s Phase 2b U.S trial is ongoing in an estimated 75 patients throughout 12 sites to examine PA5108’s durability, safety and tolerability in balancing volume of intraocular pressure over time.
By expanding its exclusive pro-drug technology into the newly developed therapeutic domains, involving pediatric rare retinal diseases, the companies will double their capability to establish first-ever drug treatments for unattended patient populations.
The CEO and Board Director of PolyActiva, Jerry St. Peter, said, “This partnership covers a crucial step in PolyActiva’s growth as we extend our exclusive platform into a new therapeutic space. Joining hands with RareSight enables us to embed our PREZIA technology across and beyond glaucoma to identify the emergency unmet needs of children suffering inherited retinal disorders. This initiative mirrors our full-fledged vision to form a diversified ophthalmic portfolio that serves potential, durable and targeted effective treatments for once-unnoticed individuals.”
CEO and Founder of RareSight, Carmen Caricchio, also precise its commitment to avoid sight loss caused due to rare pediatric eye diseases. Carmen expressed its excitement to merge with the specialisation of PolyActiva’s novel drug delivery platform.
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
